PCC Rokita Past Earnings Performance
Past criteria checks 2/6
PCC Rokita has been growing earnings at an average annual rate of 32.9%, while the Chemicals industry saw earnings growing at 21.3% annually. Revenues have been growing at an average rate of 17.8% per year. PCC Rokita's return on equity is 19.4%, and it has net margins of 11.2%.
Key information
32.9%
Earnings growth rate
32.9%
EPS growth rate
| Chemicals Industry Growth | 32.6% |
| Revenue growth rate | 17.8% |
| Return on equity | 19.4% |
| Net Margin | 11.2% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24
PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19
What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Revenue & Expenses BreakdownBeta
How PCC Rokita makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,388 | 268 | 298 | 0 |
| 30 Sep 23 | 2,782 | 473 | 314 | 0 |
| 30 Jun 23 | 3,072 | 589 | 359 | 0 |
| 31 Mar 23 | 3,225 | 692 | 373 | 0 |
| 31 Dec 22 | 3,143 | 675 | 364 | 0 |
| 30 Sep 22 | 2,821 | 569 | 356 | 0 |
| 30 Jun 22 | 2,560 | 499 | 309 | 0 |
| 31 Mar 22 | 2,405 | 472 | 287 | 0 |
| 31 Dec 21 | 2,203 | 417 | 272 | 0 |
| 30 Sep 21 | 2,027 | 294 | 269 | 0 |
| 30 Jun 21 | 1,827 | 247 | 250 | 0 |
| 31 Mar 21 | 1,597 | 171 | 230 | 0 |
| 31 Dec 20 | 1,476 | 117 | 216 | 0 |
| 30 Sep 20 | 1,414 | 73 | 201 | 0 |
| 30 Jun 20 | 1,461 | 82 | 200 | 0 |
| 31 Mar 20 | 1,482 | 72 | 205 | 0 |
| 31 Dec 19 | 1,492 | 93 | 204 | 0 |
| 30 Sep 19 | 1,513 | 145 | 198 | 0 |
| 30 Jun 19 | 1,503 | 160 | 201 | 0 |
| 31 Mar 19 | 1,512 | 201 | 198 | 0 |
| 31 Dec 18 | 1,490 | 227 | 192 | 0 |
| 30 Sep 18 | 1,445 | 243 | 196 | 0 |
| 30 Jun 18 | 1,378 | 215 | 180 | 0 |
| 31 Mar 18 | 1,345 | 213 | 174 | 0 |
| 31 Dec 17 | 1,286 | 182 | 167 | 0 |
| 30 Sep 17 | 1,234 | 208 | 161 | 0 |
| 30 Jun 17 | 1,187 | 213 | 155 | 0 |
| 31 Mar 17 | 1,129 | 207 | 152 | 0 |
| 31 Dec 16 | 1,107 | 203 | 146 | 0 |
| 30 Sep 16 | 1,084 | 135 | 143 | 0 |
| 30 Jun 16 | 1,097 | 131 | 142 | 0 |
| 31 Mar 16 | 1,077 | 110 | 133 | 0 |
| 31 Dec 15 | 1,049 | 85 | 128 | 0 |
| 30 Sep 15 | 1,053 | 73 | 131 | 0 |
| 30 Jun 15 | 1,062 | 62 | 129 | 0 |
| 31 Mar 15 | 1,083 | 62 | 129 | 0 |
| 31 Dec 14 | 1,093 | 71 | 127 | 0 |
| 30 Sep 14 | 1,066 | 58 | 119 | 0 |
| 30 Jun 14 | 1,041 | 48 | 120 | 0 |
| 31 Mar 14 | 1,085 | 52 | 123 | 0 |
| 31 Dec 13 | 1,101 | 58 | 123 | 0 |
| 30 Sep 13 | 1,157 | 232 | 123 | 0 |
| 30 Jun 13 | 1,146 | 231 | 114 | 0 |
Quality Earnings: PCR has high quality earnings.
Growing Profit Margin: PCR's current net profit margins (11.2%) are lower than last year (21.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCR's earnings have grown significantly by 32.9% per year over the past 5 years.
Accelerating Growth: PCR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PCR had negative earnings growth (-60.3%) over the past year, making it difficult to compare to the Chemicals industry average (-5%).
Return on Equity
High ROE: PCR's Return on Equity (19.4%) is considered low.